

VOLUMEN XLV

NUMERUS Suppl. 2

# **LIBRI ONCOLOGICI**

**CROATIAN JOURNAL OF ONCOLOGY**

Zagreb, 2017

CROATIAN JOURNAL OF ONCOLOGY  
LIBRI ONCOLOGICI

**Publisher**

Sestre milosrdnice University Hospital Center  
University Hospital for Tumors, Zagreb, Croatia

**Editor-in-Chief**

Danko Velimir Vrdoljak

**Editors**

Lidija Beketić-Orešković, Zvonko Kusić, Božena Šarčević

**Associate Editors**

Iva Kirac – Experimental Research  
Mladen Stanec – Surgical Oncology  
Robert Šeparović – Medical Oncology  
Hrvoje Šobat – Radiation Oncology

**Technical Editor**

Anica Vrdoljak

**Editorial Board**

Gordana Brozović, Krešimir Gršić, Željko Herceg, Nada Kraljević, Ljiljana Mayer, Ivan Milas, Aleksandar Milenović, Marija Milković Periša, Marija Pastorčić-Grgić, Vesna Pavlica, Mario Puljiz, Vesna Ramljak, Andrej Roth, Sanda Šitić, Ljiljana Štefančić, Tiha Vučemilo

**Editorial Council**

D. Babić (Zagreb, Croatia), V. Banović (Zagreb, Croatia), A. Bolanča (Zagreb, Croatia), D. Chudy (Zagreb, Croatia), M. Ćorić (Zagreb, Croatia), T. Čufer (Ljubljana, Slovenia), N. Đaković (Zagreb, Croatia), D. Eljuga (Zagreb, Croatia), G. Fisher (Stanford, USA), M. Gamulin (Zagreb, Croatia), D. Gugić (Osijek, Croatia), H. Haler (Rijeka, Croatia), J. Jassem (Gdansk, Poland), A. Juretić (Zagreb, Croatia), A. Karamarković (Belgrade, Serbia), D. Kalafatić (Zagreb, Croatia), S. Kaštelan (Zagreb, Croatia), Ž. Kaštelan (Zagreb, Croatia), M. Klarica (Zagreb, Croatia), S. Levanat (Zagreb, Croatia), D. Marčinko (Zagreb, Croatia), S. Orešković (Zagreb, Croatia), P. Ozretić (Zagreb, Croatia), S. Ž. Pavletić (Bethesda, USA), R. Pirker (Wien, Austria), M. Solarić (Zagreb, Croatia), B. I. Šikić (Stanford, USA), E. Vrdoljak (Split, Croatia), M. Zovak (Zagreb, Croatia)

---

**Indexed in EMBASE/Excerpta Medica**

---

**Editorial Office:**

LIBRI ONCOLOGICI, Ilica 197, 10 000 Zagreb, Croatia, P.O. Box 427,  
Phone (385 1) 37 83 522, Fax (385 1) 37 75 536  
Web site: <http://hrcak.srce.hr/libri-oncologici>  
e-mail: [libri.oncologici@kbcsml.hr](mailto:libri.oncologici@kbcsml.hr)

The journal is published three times a year. Orders can be placed directly to the Editorial Office.

Price per copy 60 HRK. Annual subscription rates in Croatia: 300 HRK + VAT for institutions, 150 HRK + VAT for individuals and 60 HRK + VAT for students, to be remitted with Hrvatska poštanska banka, account HR31 2390 0011 1004 1610 4 Ref.No.3 (for LIBRI ONCOLOGICI).

Annual subscription abroad - equivalent of US\$ 50 to be paid into the foreign currency account with Hrvatska poštanska banka, IBAN: HR31 2390 0011 1004 1610 4 (Ref.No.3), BIC code: HPBZHR2X (for LIBRI ONCOLOGICI)

Cover Design: Osman Berberović

Typesetting and printed by DENONA d.o.o., Zagreb



**9. godišnji sastanak  
Hrvatskog društva za internističku onkologiju  
Hrvatskog liječničkog zbora  
s međunarodnim sudjelovanjem**

**11. radni sastanak  
Sekcije za onkološku farmaciju Hrvatskog farmaceutskog društva  
s međunarodnim sudjelovanjem**

**Hrvatsko društvo za internističku onkologiju Hrvatskog liječničkog zbora  
Sekcija za onkološku farmaciju Hrvatskog farmaceutskog društva**

*20. – 21. listopada 2017., hotel "Turist", Varaždin, Hrvatska*

**9<sup>th</sup> Symposium and Annual Meeting of Croatian Society  
for Medical Oncology of Croatian Medical Association  
with International Participation**

**11<sup>th</sup> Meeting of Oncology Pharmacy Section  
of Croatian Pharmaceutical Society  
with International Participation**

**Croatian Society for Medical Oncology, Croatian Medical Association  
Oncology Pharmacy Session, Croatian Pharmaceutical Society**

*20<sup>th</sup> – 21<sup>st</sup> October 2017, hotel "Turist", Varaždin, Croatia*

**Supplement editors:**

Damir Vrbanec

Ana Tečić Vuger

Zagreb, Croatia  
January 2018

## ORGANIZER

Croatian Society for Medical Oncology, Croatian Medical Association  
Croatian Medical Association  
Section for Oncology Pharmacy, Croatian Pharmaceutical Society  
Croatian Pharmaceutical Society  
Faculty of Pharmacy and Biochemistry  
European Society for Oncology Pharmacy – ESOP  
Croatian Pharmacy Chamber

### Chair of the Organizing Committee

Damir Vrbanec

### Organizing Committee

<i>Dahna Arbanas</i>	<i>Vesna Pavlica</i>
<i>Ivan Bilić</i>	<i>Stjepko Pleština</i>
<i>Borislav Belev</i>	<i>Marko Skelin</i>
<i>Zlatko Dembić</i>	<i>Robert Šeparović</i>
<i>Natalija Dedić Plavetić</i>	<i>Darko Takač</i>
<i>Renata Dobrila Dintinjana</i>	<i>Ana Tečić Vuger</i>
<i>Davorin Herceg</i>	<i>Dragan Trivanović</i>
<i>Martina Kranjec Šakić</i>	<i>Željko Vojnović</i>
<i>Marta Kučan</i>	<i>Sanda Vladimir – Knežević</i>
<i>Sven Kurbel</i>	<i>Damir Vrbanec</i>
<i>Klaus Meier</i>	<i>Darko Županc</i>

### Sponsors & Donators

Roche  
Astellas  
Bayer  
Pliva  
Sandoz  
Abbott  
Amgen  
AstraZeneca  
Celgene  
Lilly  
GM PharmaZagreb d.o.o.  
Janssen  
Krka  
Medical Intertrade  
Merck  
MSD  
Novartis  
Pfizer  
Sanofi Genzyme  
Servier  
Stada

## Contents

### ORAL PRESENTATION

Silovski T. <b>S1 - What's new in neoadjuvant treatment of breast cancer?</b> . . . . .	3
Tečić Vuger A, Šeparović R. <b>S2 - Genetic analysis in breast cancer</b> . . . . .	4
Čonkaš M. <b>S3 - News in the neoadjuvant therapy of rectal cancer</b> . . . . .	5
Silovski T. <b>S4 - ESMO Highlights</b> . . . . .	6
Kurbel S, Mihaljević S. <b>S5 - Logic in interpreting clinical trial results: Comparison between inductive and deductive reasoning</b> . . . . .	7
Gnjidić M. <b>S6 - News in the treatment of urogenital cancers</b> . . . . .	8
Dobrića Dintinjana R, Redžović A. <b>S7 - Personalised therapy of hepato-pancreato-biliary malignancies</b> . . . . .	9
Belev B. <b>S8 - News in gastrointestinal oncology</b> . . . . .	10
Kulić A. <b>S9 - Metabolomics-metabolic phenotype of cancer</b> . . . . .	11
Kurbel S, Dmitrović B. <b>S10 - Emerging importance of Thrombospondin-1 and Endothelin-1 in cancer development and growth</b> . . . . .	12
Dedić Plavetić N. <b>S11 - Novel treatment strategies in breast cancer</b> . . . . .	13
Ladenhauser T. <b>S12 - Dose Dense Chemotherapy in Adjuvant Treatment of Early Breast Cancer - Pro Arguments</b> . . . . .	14

Budisavljević A.	
<b>S13 – Dose dense chemotherapy, is there a catch?</b> . . . . .	15
Pavlović M.	
<b>S14 - Surgery after neoadjuvant treatment for rectal cancer</b> . . . . .	16
Prejac J.	
<b>S15 - Watch and wait approach to rectal cancer</b> . . . . .	17
Vrbanec J.	
<b>S16 - Role of Family medicine physician in treatment of oncologic patients</b> . . . . .	18

## POSTERS

Krpina K, Drpa G, Budimir B, Ćuk B, Lampalo M, Kukulj S, Jakopović M, Samaržija M.	
<b>P1 - ALK-rearranged lung non small cell carcinoma with CNS metastasis responding to alectinib: a case report</b> . . . . .	21
Lonjak N, Bajić Ž, Vuković P, Raguž J, Nikles I, Badžek I, Tečić Vuger A, Pavlović M, Šeparović R.	
<b>P2 - Predictors of response to neoadjuvant treatment in estrogen receptor-positive breast cancer at the University Hospital for Tumors, Sestre milosrdnice University Hospital Center; a retrospective cohort study</b> . . . . .	22
Jurčić P.	
<b>P3 - Treatment of platinum- and cetuximab-refractory hypopharyngeal cancer; a case report</b> . . . . .	23
Maloševac S, Popek I, Brkić I, Šeparović R.	
<b>P4 - Public health significance of lung cancer in Sisak, Croatia-Moslavina County</b> . . . . .	24
Mandić S, Ćuk B, Tolj I, Bilobrk J, Radić P, Jakić-Razumović J, Dedić Plavetić N, Vrbanec D.	
<b>P5 - Clinical and molecular characteristics of triple-negative early breast cancer patients in University Hospital Centre Zagreb</b> . . . . .	25
Vuković P, Badžek I, Raguž J, Lonjak N, Nikles I, Šeparović R.	
<b>P6 - Are we burnt out from our work? - signs of burnout in Medical Oncology residents</b> . . . . .	26
Badžek I, Vuković P, Raguž J, Nikles I, Lonjak N, Šeparović R.	
<b>P7 – Job satisfaction in Medical Oncology residents</b> . . . . .	27
Krstić C, Lonjak N, Vuković P, Šahbazović A, Raguž J, Šeparović R.	
<b>P8 – Our experience in management of metastatic HER2-positive breast cancer with trastuzumab emtansine</b> . . . . .	28
Radmilović Varga Lj, Ječmenica D, Kolarić V.	
<b>P9 – Survival rates as moving targets: lung cancer target therapy amplifies survival expectations</b> . . . . .	29

Ćuk B, Krpina K, Budimir B, Drpa G, Kukulj S. <b>P10 – An unusual case of rhabdomyosarcoma as anterior mediastinal mass, in the clinical presentation of Superior Vein Cava Syndrome</b> . . . . .	30
Maloševac S, Ćuk B, Mandić S, Pacić-Hardi N. <b>P11 - Pericardial effusion as the first manifestation of locally advanced pulmonary adenocarcinoma in emergency services; case report</b> . . . . .	31
Prejac J, Goršić I, Vidović M, Golem H, Kekez D, Librenjak N, Pleština S. <b>P12 - Comparative effectiveness of nab-paclitaxel plus gemcitabine vs gemcitabine plus cisplatin or gemcitabine alone for the first-line treatment of pancreatic adenocarcinoma in the University Hospital Centre Zagreb</b> . . . . .	32
Radmilović Varga Lj, Križić M, Kulić A, Podolski P, Bašić Koretić M, Herceg D, Vrbanec D, Dedić Plavetić N. <b>P13 – Do patients from routine practice reflect clinical study population? First line treatment of metastatic HER2 positive breast cancer in University Clinical Centre Zagreb</b> . . . . .	33
Reljić D, Paić M, Grubišić-Čabo R, Bošnjak M, Mojsović A, Grubišić-Čabo F. <b>P14 - The meaning of positive surgical margins in patients whom partial nephrectomy has been made because of kidney cancer</b> . . . . .	34
Nalbani M, Simetić L. <b>P15 - Doege-Potter syndrome: hypoglycemia secondary to solitary fibrous tumors; case report</b> . . . . .	35
Nikles I, Veliki Dalić I, Nikles S, Vuković P, Raguž J, Lonjak N, Šeparović R. <b>P16 - Prognostic value of lymphovascular invasion (LVI) in breast cancer patients with clinically node-negative axilla</b> . . . . .	36
Raguž J, Vuković P, Nikles I, Lonjak N, Krstić C, Šahbazović A, Bilić Knežević S, Miletić M, Šeparović R. <b>P17 – Mobile palliative teams and patient content with palliative care - experience from University hospital for tumors</b> . . . . .	37
Tomljanović I, Bukovica A, Skočilić I, Belac-Lovasić I. <b>P18 – Case report: Patient with HER2 positive breast cancer and luminal A metastases in the scalp</b> . . . . .	38
Kovač M. <b>P19 – Topics patients would like to confer about with an oncologist before the onset of systemic treatment</b> . . . . .	39
Kardum Fučak I. <b>P 20 – A case report: Occurrence of IgM mediated - autoimmune anemia after 1<sup>st</sup> application of taxane in neoadjuvant setting for hormone receptor positive, HER2 negative locally advanced breast cancer</b> . . . . .	40
Bitar L, Seiwerth F, Krpina K, Koršić M, Kukulj S, Pleština S, Samaržija M, Jakopović M. <b>P 21 – Osimertinib in the treatment of patients with T790M mutation</b> . . . . .	41

Tečić Vuger A, Lonjak N, Vuković P, Pavlović M, Šeparović R. <b>P 22 – The Correlation between findings of preoperative MR and definitive PHD of the primary tumor after neoadjuvant treatment in breast cancer patients . . . . .</b>	42
Demser M, Belev B. <b>P23 – Evaluation of <i>burn-out</i> syndrome in oncology employees . . . . .</b>	43
Sirotković-Skerlev M, Dedić Plavetić N, Vrbanec D, Bilić I, Belev B, Sedlić F, Kovač Z, Kulić A. <b>P 24 – Analisis of circulating leptin in breast cancer patients . . . . .</b>	44
Kamenečki V, Lonjak N, Tečić Vuger A, Šeparović R. <b>P 25 - Influence of upper-body function on the quality of life in patients treated with adjuvant systemic antineoplastic treatment at the University Hospital for Tumors . . . . .</b>	45
<b>AUTHOR INDEX . . . . .</b>	46